Project Details
Description
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
| Status | Active |
|---|---|
| Effective start/end date | 7/24/23 → 3/31/27 |
Funding
- OTSUKA PHARMACEUTICAL DEV. & COMM., INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.